IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions
Meet the 2026 IPC International Fellows, eight internationally selected clinicians and researchers advancing evidence-based psoriasis care and global collaboration through
Discover how the 2025 IPC International Fellows navigated a year of global learning, collaboration, and growth to help advance psoriasis
Dr. Francis Lai reflects on his IPC International Fellowship journey with Professor Ricardo Romiti, highlighting their work on psoriasis care,
The 2024 IPC International Fellows reflect on their global dermatological journey, sharing their unique experiences, challenges, and achievements from a
In this interview, we catch up with Dr. Matthew Vesely, a 2021 IPC Fellow. He shares insights on his journey
In this interview, we reconnect with Dr. Rebecca Nguyen, a 2019 IPC Fellow. She generously shares her valuable insights and
Catch up with 2021 IPC Fellow Professor Álvaro González-Cantero as he shares insights into his experience, achievements, and challenges since
Catch up with 2018 IPC Fellow Dr. Filip Rob as he shares insights into his experience, achievements, and challenges since
Explore the global dermatological journey of the 2023 IPC International Fellows. Learn about their diverse experiences, challenges, and triumphs as
Catch up with 2018 IPC Fellow Dr. Daniela Armijo as she shares insights into her experience, achievements, and challenges since
Catch up with 2018 IPC Fellow Dr. Jia Qi Chen as she shares insights into her experience, achievements, and challenges
Explore the journey of Leandro Leite in the IPC Fellowship Program, discovering his background, research achievements, program insights, and unique
Learn about Albert Duvetorp’s experience as a 2022 participant in IPC’s International Fellowship Program. In this exclusive interview, he shares
Join the IPC International Fellowship Program to advance your career in psoriasis care. Receive mentorship, networking, and unique opportunities. Applications
Learn about Natalia Merino”s experience as a 2022 participant in IPC’s International Fellowship Program. In this exclusive interview, she shares
Learn about Lucas Galimany’s experience as a 2022 participant in IPC’s International Fellowship Program. In this exclusive interview, he shares
Learn about Mona El-Kalioby’s experience as a 2022 participant in IPC’s International Fellowship Program. In this exclusive interview, she shares
Learn about Juul van den Reek’s experience as a 2022 participant in IPC’s International Fellowship Program. In this exclusive interview,
A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.
In this article, IPC Board Member Lluís Puig, MD, PhD, gives his expert commentary on two randomized trials showing that ixekizumab plus tirzepatide outperforms ixekizumab alone for skin clearance, joint control, and weight loss in psoriasis and PsA.
IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.
Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.
IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.
In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.
